Table 3.
Summary of most common (≥2% incidence) treatment-related adverse events
| Adverse event n (%) | PALO (N = 136) | NEPA100 (N = 135) | NEPA200 (N = 138) | NEPA300 (N = 136) | APR + OND (N = 134) |
|---|---|---|---|---|---|
| Patients with any adverse event | 67 (49.3) | 55 (40.7) | 71 (51.4) | 68 (50.0) | 71 (53.0) |
| Patients with any treatment-related adverse event | 17 (12.5) | 18 (13.3) | 24 (17.4) | 21 (15.4) | 26 (19.4) |
| Hiccups | 5 (3.7) | 5 (3.7) | 5 (3.6) | 7 (5.1) | 0 (0) |
| Headache | 2 (1.5) | 1 (0.7) | 3 (2.2) | 1 (0.7) | 3 (2.2) |
| Leukocytosis | 3 (2.2) | 2 (1.5) | 1 (0.7) | 2 (1.5) | 1 (0.7) |
| Alanine aminotransferase increased | 1 (0.7) | 1 (0.7) | 3 (2.2) | 2 (1.5) | 2 (1.5) |
| Aspartate aminotransferase increased | 1 (0.7) | 1 (0.7) | 3 (2.2) | 1 (0.7) | 2 (1.5) |
| Dyspepsia | 2 (1.5) | 0 (0) | 4 (2.9) | 1 (0.7) | 0 (0) |
| Bradycardia | 0 (0) | 1 (0.7) | 0 (0) | 0 (0) | 3 (2.2) |
| Bundle branch block | 0 (0) | 1 (0.7) | 0 (0) | 3 (2.2) | 0 (0) |
| Anorexia | 3 (2.2) | 0 (0) | 0 (0) | 1 (0.7) | 0 (0) |